Ferric maltol

(Accrufer®)

Accrufer®

Drug updated on 4/18/2024

Dosage FormCapsule (oral; 30 mg)
Drug ClassIron replacement products
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of iron deficiency in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Ferric maltol (Accrufer) is indicated for the treatment of iron deficiency in adults. It has shown effectiveness in increasing hemoglobin levels, particularly among patients with inflammatory bowel disease (IBD), compared to placebo.
  • A systematic review/meta-analysis focused on Accrufer's role in treating iron deficiency anemia (IDA) and another unrelated study were reviewed. The primary analysis was based on the comprehensive review directly related to Accrufer's clinical use.
  • The systematic review included studies involving 1,670 participants primarily suffering from IBD. This population frequently experiences IDA, making it a relevant group for assessing Accrufer’s efficacy and safety.
  • Comparisons between ferric maltol and other treatments revealed that while IV ferric carboxymaltose may be superior to some options like iron sucrose, specific data comparing it directly with oral ferric maltol are not detailed across all comparisons.
  • In terms of safety outcomes, no significant differences were found across various treatments including Accrufer, regarding serious adverse events or withdrawals due to therapy; however, this conclusion was based on very low-certainty evidence. Oral preparations might lead more often to withdrawal due to adverse events than intravenous ones, indicating potential tolerability issues associated with oral administration methods.
  • More research targeting subgroups within the IBD population such as children versus adults or those at different stages of disease activity could provide further insights into how best to utilize this drug within broader treatment protocols, given its apparent effectiveness against placebo but lack of high certainty comparative evidence against other prevalent therapies, especially intravenous ones.

Product Monograph / Prescribing Information

Document TitleYearSource
Accrufer (ferric maltol) Prescribing Information.2022Shield Therapeutics Inc, North Austin, TX

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Interventions for treating iron deficiency anaemia in inflammatory bowel disease.2021The Cochrane Database of Systematic Reviews
Interventions for fatigue in inflammatory bowel disease.2020The Cochrane Database of Systematic Reviews

Clinical Practice Guidelines